Jeffrey Zwicker Joins Memorial Sloan Kettering Cancer Center as Chief of the Hematology Service

Jeffrey Zwicker, MD

Jeffrey Zwicker, MD, has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and Beth Israel Deaconess Medical Center (BIDMC), where he served as Chief of Benign Hematology in the Division of Hematology since 2017. Dr. Zwicker succeeds MSK’s Interim Hematology Service Chief, Marcel van den Brink, MD, PhD.

“Dr. Zwicker is an esteemed physician and researcher who has dedicated his career to education, mentorship, and career development for students, house staff, fellows, and faculty,” said Deb Schrag, MD, Chair of the Department of Medicine at MSK. “His expertise will strengthen this already robust group of world-renowned hematologists. We look forward to seeing this service thrive under his leadership.”

“Dr. Zwicker has a unique expertise in the management of cancer-associated thrombosis, which is a major complication for many cancer patients. He has performed practice-changing clinical trials to develop better strategies to prevent or treat this important problem,” said Dr. van den Brink. “We are thrilled to welcome him to MSK.”

Dr. Zwicker has conducted extensive research in thrombosis, with an emphasis on cancer-associated thrombosis, and has held leadership positions in national and international professional organizations dedicated to thrombotic disease. He serves as the Chair of the International Society on Thrombosis and Haemostasis Inc.’s (ISTH) subcommittee on hemostasis and thrombosis and previously acted as the Vice-Chair and Chair of the American Society of Hematology’s (ASH’s) subcommittee on thrombosis and vascular biology. Within his new role, Dr. Zwicker will support MSK’s clinical trials focused on identifying patients at a high risk of developing cancer-associated thrombosis and other blood disorders. He will also assist with other physician-led research projects in these areas to work toward new therapeutic approaches to combat these conditions. 

“I joined MSK because it is a world-class institution with an amazing breadth of expertise across the spectrum of cancer diagnoses and complications,” explained Dr. Zwicker. “I look forward to becoming a part of the collaborative, multi-disciplinary nature of the personalized and compassionate cancer care that MSK delivers to all patients.”

Dr. Zwicker received a Bachelor of Science Degree at the University of California, Berkeley, a Masters of Medical Science at Harvard Medical School, and a Medical Degree at Penn State University. He completed his residency and fellowship training at BIDMC, where he led a National Institutes of Health (NIH)-funded research program focused on finding novel therapeutic approaches to treat thrombosis.

Name: John Connolly
Phone: (917) 816-6551
Email: [email protected]